Anti-TNF therapy attenuates the diagnostic utility of leucine-rich α2-Glycoprotein 1 for endoscopic activity in ulcerative colitis
Akihiro Dejima, Hajime Takatori, Masaki Miyazawa, Hirofumi Okafuji, Tomoyuki Hayashi, Akihiro Seki, Kouki Nio, Noriho Iida, Shinya Yamada, Tetsuro Shimakami, Tadashi Toyama, Taro Yamashita · 2026
Read Anti-TNF therapy attenuates the diagnostic utility of leucine-rich α2-Glycoprotein 1 for endoscopic activity in ulcerative colitis by Akihiro Dejima, Hajime Takatori, Masaki Miyazawa, Hirofumi Okafuji, Tomoyuki Hayashi, Akihiro Seki, Kouki Nio, Noriho Iida, Shinya Yamada, Tetsuro Shimakami, Tadashi Toyama, Taro Yamashita (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13562854.txt.
Description
Akihiro Dejima and colleagues warn that a fashionable colitis blood test goes blind in patients on anti-TNF drugs, in this study from twenty twenty-six. The marker, LRG1, signals gut wall inflammation in ulcerative colitis and can spare patients some colonoscopies. But LRG1 production partly depends on TNF, the very signal anti-TNF therapy blocks. One hundred twenty-seven paired scope-and-blood evaluations were analyzed.
Overall the marker discriminated active disease well. Split by therapy, it collapsed: near chance under anti-TNF, excellent without it. Forty-five percent of active cases on anti-TNF read falsely quiet, and the drug independently predicted false negatives ninefold. Under JAK inhibitors, by contrast, the marker shone. The authors instruct clinicians to read LRG1 through the prescription list: a calm value on anti-TNF may be the drug talking, not the bowel healing.
Catalog record
| CREATOR | Akihiro Dejima, Hajime Takatori, Masaki Miyazawa, Hirofumi Okafuji, Tomoyuki Hayashi, Akihiro Seki, Kouki Nio, Noriho Iida, Shinya Yamada, Tetsuro Shimakami, Tadashi Toyama, Taro Yamashita |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |